Medivir AB (MVRBF) Release: A Supplemental New Drug Application Has Been Submitted To The FDA For Simeprevir In Combination With Sofosbuvir
5/7/2014 9:25:23 AM
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that Janssen has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Association (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analogue NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Help employers find you! Check out all the jobs and post your resume.
comments powered by